Novacyt Stock

Novacyt Net Debt

The Net Debt of Novacyt (ALNOV.PA) as of Sep 5, 2026 is -18.58 M GBP. In the previous year, Net Debt was -29.64 M GBP — a change of -37.30% (higher).

Net Debt

-18.58 MGBP

YoY

-37.30%

Last updated:

Net Debt of Novacyt is 2026 -18.58 M GBP. Net Debt of Novacyt was 2025 -29.64 M GBP. It decreases by -37.30% higher compared to the previous year.

The Novacyt Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2017
-400,900.00 GBP
Jan 1, 2018
3.67 M GBP
Jan 1, 2019
7.05 M GBP
Jan 1, 2020
-89.40 M GBP
Jan 1, 2021
-99.88 M GBP
Jan 1, 2022
-86.11 M GBP
Jan 1, 2023
-29.64 M GBP
Jan 1, 2024
-18.58 M GBP
The Novacyt Net Debt history
YEARNet DebtYoY
-18.58 MGBP-37.30%
-29.64 MGBP-65.58%
-86.11 MGBP-13.79%
-99.88 MGBP+11.73%
-89.40 MGBP-1,368.57%
7.05 MGBP+91.86%
3.67 MGBP-1,016.19%
-400,900.00GBP-113.76%
2.91 MGBP+73.25%
1.68 MGBP-227.81%
-1.32 MGBP
Access this data via the Eulerpool API

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Net Debt of Novacyt is -18.58 M GBP in 2026.

Net Debt of Novacyt changed from -29.64 M GBP to -18.58 M GBP, representing a -37.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Novacyt since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Novacyt historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Novacyt

All Key Metrics — Novacyt